3X Genetics has raised $3.16 million toward a planned $4 million seed round.
Already a Subscriber? Log in
Get Instant Access to This Article
Subscribe to Worcester Business Journal and get immediate access to all of our subscriber-only content and much more.
- Critical Central Massachusetts business news updated daily.
- Immediate access to all subscriber-only content on our website.
- Bi-weekly print or digital editions of our award-winning publication.
- Special bonus issues like the WBJ Book of Lists.
- Exclusive ticket prize draws for our in-person events.
Click here to purchase a paywall bypass link for this article.
Worcester-based biotech startup 3X Genetics has raised $3.16 million in seed funding.
3X Genetics has raised $3.16 million toward a planned $4 million seed round, according to a Form D filing with the U.S. Securities and Exchange Commission on Wednesday. The company is seeking the additional $840,014.
Founded in 2021, 3X Genetics develops genetic testing kits to identify rare genetic disorders. Specializing in the analysis of long genetic samples, the firm partners with biopharmaceutical companies, hospitals, and universities for high-volume testing and research.
3X was founded by CEO Kevin Donahue. Steven Oldenburg serves as its chief technology officer.
The lead investor and number of investors were not disclosed. WBJ has reached out to 3X Genetics for further details.Â
In 2023, the company completed a pre-seed raise for an undisclosed amount, led by New Hampshire-based Alumni Ventures, according to company financial tracker Crunchbase.Â
3X Genetics testing kits are provided through a patient’s primary care provider or specialist. Patients mail saliva samples to the firm’s laboratory, where they are analyzed for applications in therapy development.
The company is located at startup incubator Massachusetts Biomedical Initiatives in Worcester. In the past 26 years, MBI has helped launch more than 188 companies that have generated more than 1,800 jobs and raised more than $1.4 billion, according to MBI’s website.Â
Other current MBI companies include protein developer Conigen Bioscience and biotech firm Leal Therapeutics.Â
Mica Kanner-Mascolo is a staff writer at Worcester Business Journal, who primarily covers the healthcare, manufacturing, and higher education industries.
